Nandrolone: long ester

Nandrolone Decanoate (Deca-Durabolin)

Nandrolone decanoate (Deca-Durabolin) had a terminal half-life of 7 to 12 days after a single intramuscular injection in healthy men; the app's figure is 9 days.1

Strong evidence (the app's grade, not a conclusion of the sources; the pooled review rates its adverse-event evidence low certainty)Get the app

Level after one dose

Nandrolone Decanoate (Deca-Durabolin) after one dose: 50% at ~9 days, 25% at 18 days, 12.5% at 27 days.

Drawn from the half-life in the app's model, ~9 days. The model's figures

Deca Durabolin 50 mg/ml solution for injection, with NV Organon as the holder in an Irish Medicines Board document printed 2 July 2010, is described there as "an injectable anabolic preparation" whose pharmacologically active substance is nandrolone.2 The same document lists its use "In the management of conditions associated with catabolism and negative nitrogen balance such as debility, burns, osteoporosis, refractory anaemia and renal failure".2 The US label for nandrolone decanoate injection USP (Watson Laboratories, literature revised March 2006) states that it "is indicated for the management of the anemia of renal insufficiency".3

The figures row above is the app's own, and the sources below differ from several of its figures: a terminal half-life of 7 to 12 days against the app's 9 days (216 hours), a peak at 30 to 72 hours against 48 hours, no bioavailability percentage against 95%, and no regimen above 200 mg a week against the app's 200 to 600 mg a week.1,2,3 No cited source says what a typical dose is, and the evidence label above is the app's grade, not a conclusion of the sources: Camara and colleagues rate their adverse-event result as low certainty.7

Kicman, British Journal of Pharmacology, 2008, writes that nandrolone is "readily converted by the enzyme 5α-reductase into 5α-dihydro-19-nortestosterone" in androgenic tissue, a metabolite that "binds with weaker affinity to the androgen receptor compared with the parent steroid".4 In skeletal muscle the review states that 5α-reductase activity is negligible, so the parent steroid "itself binds with strong affinity to the androgen receptor".4 The tissue difference rests on in vitro studies in rat tissue, in which 5α-reductase activity was "negligible, if at all, in skeletal muscle such as the levator ani and thigh muscle"; Kicman writes "If the model is correct" of the extension of reduced androgenic activity to human non-genital tissues such as the male patterns of facial and body hair growth.4 He adds that "complete dissociation has not been achieved with any anabolic steroid synthesized, and, therefore, the chronic administration of these drugs, even those with a very high myotrophic–androgenic index value, such as found with nandrolone (19-nortestosterone), will result in hirsutism and, eventually, virilization of women and children".4 The Irish authorisation states that, compared with testosterone, nandrolone "has an enhanced anabolic and reduced androgenic activity", which "has been demonstrated in animal bioassays and explained by receptor binding studies".2,4

Sources describe aromatization differently: Chung and colleagues, 2007, call nandrolone "a non-amplifiable and non-aromatizable pure androgen", Crawford and colleagues, 2003, a "minimally aromatizable analog" of testosterone, and Camara and colleagues, 2025, a compound with "anabolic and mild estrogenic properties via aromatization".5,6,7 Bijlsma and colleagues, 1982, in a pilot study of male patients with rheumatoid arthritis (no number, dose or duration in the record), reported a rise in serum oestrone and explained it by "peripheral aromatizing of ND to oestrogens".8

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~9 days
Bioavailability
95%
Typical dose
200–600 mg/week
Route
IM
Time to peak
~48 h
Table 3.1Half-life and pharmacokinetics5 rows
MeasureApp figureSource figure
Half-life~9 days (216 h)Terminal half-life of 7 to 12 days after a single intramuscular injection of 50, 100 or 150 mg in healthy young men (Bagchus and colleagues, 2005).1 A half-life time of 8 days after 50 mg in 6 volunteers (Belkien and colleagues, 1985).9 A half-life of 6 days for release from the injection site and 4.3 hours for the combined processes of hydrolysis, distribution and elimination (Wijnand and colleagues, 1985; Irish authorisation).10,2
Bioavailability95%None of the cited sources gives a percentage. Minto and colleagues, 1997, gave 100 mg of a nandrolone ester to 23 healthy men, 16 of them nandrolone decanoate (groups of 6, 5 and 5), and reported from a modelled analysis that the highest bioavailability and peak nandrolone levels were after the 1 ml gluteal injection (5 men), compared with 4 ml and with the deltoid, without giving a percentage.11
Time to peak~48 hPeak serum nandrolone after 30 h (50 and 100 mg) and 72 h (150 mg) in healthy men.1
Duration~28 days (672 h)The Irish authorisation states that the ester "gives the preparation duration of action of about three weeks after injection".2
RouteIMThe US label states the injection is intended for deep intramuscular injection only; Singh and colleagues gave it subcutaneously.3,12

Deeper analysis: single-dose pharmacokinetics (Bagchus and colleagues, 2005)

Bagchus and colleagues, Journal of Clinical Endocrinology and Metabolism, 2005, gave healthy young men a single intramuscular injection of nandrolone decanoate, 50 mg (n = 20), 100 mg (n = 17) or 150 mg (n = 17), and sampled blood for up to 32 days.1 The peak serum concentration ranged from 2.14 ng/ml at 50 mg to 4.26 ng/ml at 100 mg and 5.16 ng/ml at 150 mg, and serum concentrations and the area under the curve "increased proportionally with the dose administered".1 In urine, 19-norandrosterone or 19-noretiocholanolone was detected before treatment in 5 of 37 men (14%), and in the 150 mg group, presumed not to have used nandrolone before, for up to 6 months in 8 of 12 (67%) for 19-noretiocholanolone and 10 of 12 (83%) for 19-norandrosterone.1 The first author's listed affiliation is Organon, Oss, the company named as holder in the Irish document; the record names no funder and no limitations statement.1,2 The chart below is a model built on the app's half-life and time to peak, not a measured curve; its three intervals are schedules from cited trials, not their doses, and the dose slider stops at 200 mg, the largest dose in a cited regimen.13,14,15

Level over 6 weeks

Interval between doses

Level, as a share of the peak after one 100 mg dose

As studied: weekly (dialysis trial)13, every 2 weeks (HIV trial)14, every 3 weeks (osteoporosis trial)15.

An illustration from a pharmacokinetic model using a half-life of 216 hours (9 days). It is not a measured level or a suggested dose.

4

What nandrolone decanoate products contain per mL

The US label from Watson Laboratories describes a sterile solution containing per mL either 100 mg of nandrolone decanoate with benzyl alcohol 10%, or 200 mg with benzyl alcohol 5%, in sesame oil.3

Table 4.1What nandrolone decanoate products contain per mL4 rows
ProductDocumentStrengthContainer or status
Nandrolone Decanoate Injection USPUS label, Watson Laboratories3100 mg per mLMultiple dose vials of 2 mL, in cartons of 10
Nandrolone Decanoate Injection USPUS label, Watson Laboratories3200 mg per mLSingle dose vials of 1 mL, in cartons of 25
Deca Durabolin solution for injection (syringe)Irish authorisation, NV Organon250 mg per mlSyringe; per ml also 0.1 ml of benzyl alcohol and up to 1 ml of arachis oil
DECA DURABOLIN INJ 50MG/MLHealth Canada Drug Product Database, Organon Canada1650 mg per mlStatus Cancelled Post Market, status date 1996-09-10

The converter below is arithmetic only: it multiplies a volume by a strength in mg per mL, starting from the US label's 200 mg per mL, and the strength printed on a container's own label is the figure that applies to that container.3

Strength converter

US label strength: 200 mg per mL3

Arithmetic only: the amount is the volume times the strength. The vial's own label states its strength.

5

Human studies

Table 5.1Human studies7 rows
Study and yearDesignPeopleDose and lengthMain result
Johansen and colleagues, 199913Randomised, double-blind, placebo-controlled.29 patients on dialysis (14 nandrolone, 15 placebo).100 mg intramuscular weekly for 6 months.Lean body mass +4.5 (SD 2.3) kg on nandrolone and +1.9 (SD 1.6) kg on placebo (P = .005 between groups); grip strength did not change in either group; peak oxygen consumption rose on nandrolone, not to a statistically significant degree.
Johansen and colleagues, 200617Randomised 2 x 2 factorial: double-blind nandrolone or placebo, and resistance exercise.79 patients on hemodialysis; 68 completed, and the record gives no reason for the other 11.17100 mg (women) or 200 mg (men) weekly for 12 weeks.Lean body mass +3.1 ± 2.2 kg in the patients who received nandrolone (P < 0.0001), with no placebo comparison given in the record; exercise did not significantly increase it; quadriceps area rose with exercise (P = 0.01) and nandrolone (P < 0.0001), additively.17
Gold and colleagues, 200614Multicentre, randomised, double-blind, placebo-controlled, with a testosterone arm.303 HIV-positive men with weight loss, low body mass index or low body cell mass.150 mg, or testosterone 250 mg, or placebo, every 2 weeks for 12 weeks.Against placebo, fat-free mass +1.34 kg (95% CI 0.60 to 2.08) and weight +1.48 kg (0.82 to 2.14); against testosterone, weight +1.00 kg (0.27 to 1.74), and fat-free mass +0.69 kg (-0.13 to 1.51), not significant.
Frisoli and colleagues, 200515Randomised, double-blind, placebo-controlled; all given 500 mg calcium daily.65 osteoporotic women older than 70 (32 nandrolone, 33 placebo).50 mg every 3 weeks for 2 years.Lumbar spine density +3.4% (1 year) and +3.7% (2 years) against baseline, not reported against placebo; trochanter and femoral neck density significantly higher than placebo; new vertebral fractures 21% against 43% (p < .05).
Creutzberg and colleagues, 200320Randomised, double-blind, placebo-controlled; all in a pulmonary rehabilitation programme.63 men with COPD.50 mg intramuscular on days 1, 15, 29 and 43.Fat-free mass +1.7 kg (SD 2.5) against +0.3 kg (SD 1.9) (p = 0.015); muscle function, exercise capacity and health status improved in both groups to the same extent.
Crawford and colleagues, 20036Randomised, double-blind, placebo-controlled, with a testosterone arm.51 men on a mean daily prednisone dose of 12.6 ± 2.2 mg.200 mg every fortnight for 12 months.Muscle mass +5.8% on nandrolone, +3.5% on testosterone, -0.9% on placebo (P < 0.0001); lumbar spine density rose only on testosterone; quality of life improved on testosterone, not nandrolone or placebo.
Hartgens and colleagues, 2001; van Marken Lichtenbelt and colleagues, 200421,22Randomised, double-blind, placebo-controlled; the records do not say whether both papers report the same men.16 bodybuilders in each paper.200 mg intramuscular weekly for 8 weeks.Bone-free lean mass 59.54 ± 2.36 to 63.06 ± 2.99 kg (p < 0.025), a change from baseline during nandrolone, in one paper; fat-free mass +2.6 kg, body mass +2.2 kg and total body water +1.4 kg in the other, with the record naming no comparator for those figures; fat mass did not change significantly in either.

The records of Johansen 1999 and 2006, Gold, Frisoli, Creutzberg, Crawford, Hartgens 2001 and van Marken Lichtenbelt contain no adverse-event data.13,17,14,15,20,6,21,22 The Creutzberg record names the study drug as "Deca-Durabolin; N.V. Organon", the holder named in the Irish document.20,2

Deeper analysis: dialysis (Johansen and colleagues, 1999 and 2006)

Johansen, Mulligan and Schambelan, University of California, San Francisco, JAMA, 1999, ran the trial in a hospital outpatient dialysis unit.13 The authors concluded that "Treatment with nandrolone for 6 months resulted in a significant increase in LBM associated with functional improvement in patients undergoing dialysis".13 The record names no funder, no adverse-event data and no limitations statement.13

Deeper analysis: HIV-associated weight loss (Gold, Storer and Mulligan)

Storer and colleagues, in HIV-infected men with weight loss given 150 mg every 2 weeks for 12 weeks, report lean body mass +1.6 ± 0.3 kg on nandrolone against +0.4 ± 0.3 kg on placebo (P < 0.05), not significantly different from growth hormone (+2.5 ± 0.3 kg), and that growth hormone "was associated with greater loss of whole body fat mass and higher frequency of drug-related adverse effects and treatment discontinuations than nandrolone and placebo".18 Mulligan and colleagues, in 38 HIV-infected women given 100 mg every other week, report weight +4.6 kg and lean body mass +3.5 kg on nandrolone during 12 blinded weeks (P < .001 against baseline and placebo), and no statistically significant differences between groups in biochemical measures, grade 3 or greater toxicities or virilizing effects, and add that "a full assessment of safety cannot be made in a trial of this size".19 The records give the first author's affiliation only and name no funder and no limitations statement, so ties to a manufacturer cannot be checked from them.14,18,19 The author lists of Gold and Storer include Geurts and Harms, and Geurts TB is also an author of the Bagchus paper from Organon, but the records do not say whether these are the same people.14,18,1

Deeper analysis: postmenopausal osteoporosis (Frisoli and colleagues, 2005; Camara and colleagues, 2025)

The record of Frisoli and colleagues, Journal of Gerontology, 2005, of the Federal University of São Paulo, names no funder and no limitations statement.15 Camara and colleagues, Cureus, 2025, pooled seven trials with 293 participants and report a risk ratio for fractures of 0.37 (95% CI 0.20 to 0.69; two trials, n = 74; moderate-certainty evidence), a standardised mean difference in bone mineral density of 0.31 (0.02 to 0.59; three trials, n = 92; low certainty) and a risk ratio for adverse events of 4.59 (1.65 to 12.74; five trials, n = 234; low certainty).7 In their risk-of-bias assessment, fractures and adverse events had the highest proportion of high-risk classifications.7 They list as limitations that "small sample sizes limit the precision and generalizability of pooled estimates" and "short follow-up durations restrict the ability to evaluate long-term efficacy and sustained safety", and declare no financial support.7

Deeper analysis: healthy bodybuilders (Hartgens and colleagues, 2001; van Marken Lichtenbelt and colleagues, 2004)

Hartgens and colleagues, International Journal of Sports Medicine, 2001, of the Netherlands Centre for Doping Affairs, reported that bone-free lean mass was still increased compared with baseline 6 weeks after drug cessation.21 Van Marken Lichtenbelt and colleagues, Medicine and Science in Sports and Exercise, 2004, of Maastricht University, reported fat-free mass +2.6 kg alongside total body water +1.4 kg.22 The records name no funder and no limitations statement for either paper.21,22

6

Doses reported in studies and labels

The app's typical dose is 200 to 600 mg a week, and the regimens below are those printed in the cited labels and used in the cited studies.

Table 6.1Doses reported in studies and labels7 rows
SourceDoseFrequencyLength
US label, anemia of renal insufficiency350 to 100 mg (women), 100 to 200 mg (men)Per weekNot stated; the label says to discontinue if no hematologic improvement is seen within the first six months, and that therapy be intermittent if possible
Irish authorisation, adults225 to 50 mg initialOnce every 3 weeksNot stated
Dialysis trials13,17100 mg; 100 mg (women), 200 mg (men)Weekly6 months; 12 weeks
HIV trials14,19150 mg (Gold); 100 mg (Mulligan)Every 2 weeks12 weeks; 12 weeks blinded then 12 open label
Osteoporosis in women15,2350 mgEvery 3 weeks (Frisoli); every 3 to 4 weeks (Geusens)2 years (Frisoli)
COPD2050 mgDays 1, 15, 29 and 43Four injections; results at 8 weeks
Bodybuilders21,22200 mgOnce a week8 weeks

The US label warns that peliosis hepatis (liver and sometimes splenic tissue replaced with blood-filled cysts) is "often not recognized until life-threatening liver failure or intra-abdominal hemorrhage develops", though "withdrawal of drug usually results in complete disappearance of lesions"; that among liver cell tumours "most often these tumors are benign and androgen-dependent, but fatal malignant tumors have been reported"; and that blood lipid changes "may be very marked and could have a serious impact on the risk of atherosclerosis and coronary artery disease", although its pharmacology section says that "these changes revert to normal on discontinuation of treatment".3 It states that "Some virilizing changes in women are irreversible even after prompt discontinuance of therapy", and that stopping at the time of "mild virilism" is necessary to prevent irreversible virilization.3 The Irish authorisation lists, dependent on dose, frequency and total period of administration, undesirable effects including virilism, hirsutism, hyperlipidaemia, hypertension, hepatic function abnormal, peliosis hepatis, priapism, benign prostatic hyperplasia, decreased high density lipoprotein, decreased sperm count and increased haemoglobin, and states that a relationship between liver tumours and nandrolone esters "appears to be highly unlikely but cannot be absolutely excluded".2 It also states that "Androgenic effects (e.g. virilisation) are relatively uncommon at the recommended dosages".2

Geusens, Clinical Rheumatology, 1995, writes in a review of nandrolone decanoate in osteoporosis (50 mg every 3 to 4 weeks in women) that "Virilization occurred in around 50% of the patients (mainly hoarseness and/or hirsutism), and 9% of the patients dropped out because of this reason".23 The review adds that tolerability is higher in patients after the age of 65 to 75 years.23 In the Camara meta-analysis of five trials in postmenopausal women (n = 234), adverse events occurred in approximately 15.8% of participants on nandrolone and 3.5% on placebo (risk ratio 4.59, 95% CI 1.65 to 12.74), rated low-certainty evidence.7 The seven included trials differed in regimen (50 mg every 3 weeks or monthly) and duration (12 to 36 months).7 In the discussion the authors write that adverse events were "generally affecting more than 30% of participants", a figure that differs from the pooled 15.8% and that the paper does not reconcile, but "predominantly mild to moderate in intensity", the most common being acne, hirsutism, hair loss and vocal changes, and, citing two individual trials, that the incidence "showed a dose-dependent relationship".7 The results report that androgenic effects were "generally reversible after treatment discontinuation" and that "No serious or life-threatening events were reported".7

Chung and colleagues, 2007, gave 3 groups of 10 healthy young men weekly nandrolone decanoate 200 mg, mixed testosterone esters 200 mg or placebo for 4 weeks and concluded that "Four weeks of treatment with testosterone or nandrolone had no beneficial or adverse effects compared with placebo on cardiac function in healthy young men".5 Hartgens and colleagues, 2003, found no significant alterations in blood pressure or heart morphology and function after 8 weeks of 200 mg a week in 16 bodybuilders, and wrote that "from the present study no conclusions can be drawn of the cardiotoxic effects of long term AAS abuse".24 Hartgens and colleagues, 2004, report that the same 8-week regimen "did not influence serum triglycerides, total cholesterol, HDL-C, HDL2-C, HDL3-C, Apo-A1, and Apo-B concentrations", but lipoprotein (a) fell significantly on nandrolone (103 to 65 U/l) and by a smaller amount on placebo (245 to 201 U/l), and the authors write that the effect on atherogenesis "remains to be established"; in a separate non-blinded group of 19 men who self-administered several steroids, HDL-C fell from 1.08 (0.30) to 0.43 (0.22) mmol/l.25

The app lists total testosterone, estradiol, prolactin, hematocrit and lipids as markers to follow. In the Bijlsma pilot study of male patients with rheumatoid arthritis, testosterone, androstenedione, FSH and the testosterone/oestradiol ratio fell significantly and oestrone rose significantly, with oestradiol, SHBG, LH and cortisol unchanged.8 Creutzberg and colleagues reported increases in erythropoietic parameters only after nandrolone decanoate, with neither result below p = 0.05 (erythropoietin p = 0.067; hemoglobin p = 0.055).20 Frisoli and colleagues reported hemoglobin 14.3% above baseline (p < .01) and above placebo (p < .01) after 2 years of 50 mg every 3 weeks in osteoporotic women.15 The US label's laboratory-tests section names periodic checks of hemoglobin and hematocrit for polycythemia with high doses, of serum lipids and high-density lipoprotein cholesterol, and of liver function "because of the hepatotoxicity associated with the use of 17-alpha-alkylated anabolic steroids"; the Irish authorisation says nandrolone "lacks the C17-alpha-alkyl group that is associated with the occurrence of liver dysfunction and cholestasis".3,2

The US label states that nandrolone decanoate injection "is classified as a Schedule III controlled substance under the Anabolic Steroids Control Act of 1990", and 21 CFR 1308.13 lists nandrolone among the Schedule III anabolic steroids, "including its salts, esters and ethers".3,26 The label states that the drug "has not been shown to be safe and effective for the enhancement of athletic performance" and gives "the potential risk of serious adverse health effects" as the reason it is not for that purpose, and the Irish authorisation says such use "may carry severe risks to the user's health".3,2

WADA's 2026 Prohibited List names nandrolone (19-nortestosterone) in S1.1, anabolic androgenic steroids "when administered exogenously", within class S1 anabolic agents, which is prohibited at all times, in and out of competition, and all substances in the class are non-Specified Substances.27 Palonek and colleagues, Steroids, 2016, followed urine by GC-MS/MS for nine months in 11 healthy men given 150 mg of nandrolone decanoate and reported that "nandrolone doping can be identified 4 and 9 months after the injection of only one single dose in six and three individuals, respectively", with large inter-individual variation.28

10

What tested samples contained

Sources in this part

  1. 29Magnolini et al., 2025

Magnolini and colleagues, Harm Reduction Journal, 2025, reported a drug-checking pilot in Zurich in which 52 clients supplied 71 samples; 5 samples (7.0%) were labelled nandrolone decanoate, and "over half (52%) of the provided samples were fake", either counterfeit (25%) or of substandard quality (27%).29 The text gives no result for the nandrolone decanoate samples on their own, and the authors list selection bias and social desirability bias among the limitations.29

The sources cited here give no bioavailability percentage, no time to steady state, no regimen above 200 mg a week and no typical dose, so the app's 95%, 48 hours and 200 to 600 mg a week are not backed by them.1,2,3 Sources disagree on whether nandrolone aromatizes, and the records read for the cited trials and reviews report no prolactin measurement.5,6,7 Camara and colleagues list small samples and short follow-up as limitations of their review.7

What is the half-life of nandrolone decanoate?

The terminal half-life of nandrolone was 7 to 12 days after a single intramuscular injection of nandrolone decanoate in healthy young men, against the app's 9 days (216 hours).1

How long does nandrolone decanoate take to peak?

Peak serum nandrolone came 30 hours after 50 and 100 mg and 72 hours after 150 mg of intramuscular nandrolone decanoate in healthy men, against the app's 48 hours.1

How many mg per mL is nandrolone decanoate?

The US label from Watson Laboratories lists 100 mg per mL and 200 mg per mL, and the Irish authorisation for Deca Durabolin lists 50 mg per ml.3,2 These are product documents, not a full list, and the strength on a container's own label is the one for that container.

How long can nandrolone decanoate be detected in urine?

In 11 healthy men given 150 mg, urine was followed by GC-MS/MS for nine months, and nandrolone use could be identified 4 months after one injection in six men and 9 months after in three, with large inter-individual variation.28 In Bagchus and colleagues, 8 of 12 men (19-noretiocholanolone) and 10 of 12 (19-norandrosterone) had metabolites at 6 months after 150 mg, the last sampling point, so these are study end points and not detection limits; Bagchus counted any metabolite, while Palonek counted people in whom nandrolone doping could be identified.1

Is Deca-Durabolin banned by WADA?

WADA's 2026 Prohibited List names nandrolone (19-nortestosterone) in S1.1, anabolic androgenic steroids when administered exogenously, prohibited at all times, in and out of competition.27

Is nandrolone decanoate a controlled substance?

In the United States nandrolone decanoate injection is a Schedule III controlled substance, according to its label, and 21 CFR 1308.13 lists nandrolone among the Schedule III anabolic steroids.3,26

What side effects are reported with nandrolone decanoate?

The US label warns of peliosis hepatis (liver cysts that can go unrecognised until liver failure or intra-abdominal hemorrhage develops), liver cell tumours (most often benign, some fatal), lipid changes and virilizing changes in women, some of which are irreversible.3 A 2025 meta-analysis in postmenopausal women reported adverse events in about 15.8% on nandrolone against 3.5% on placebo (risk ratio 4.59, 95% CI 1.65 to 12.74; low-certainty evidence), and a 1995 review of osteoporosis treatment in women reported virilization in around 50% of patients and 9% dropping out for that reason, which is a different measure from any adverse event.7,23

14

References

  1. Bagchus WM, et al. Pharmacokinetic evaluation of three different intramuscular doses of nandrolone decanoate: analysis of serum and urine samples in healthy men. J Clin Endocrinol Metab 2005. PMID 15713722
  2. Irish Medicines Board. Deca Durabolin 50 mg/ml Solution for Injection (syringe), Summary of Product Characteristics, authorisation PA0964/008/002 (NV Organon), printed 2010. Irish SmPC
  3. Watson Laboratories, Inc. Nandrolone Decanoate Injection USP for intramuscular use (C-III), US label, literature revised March 2006. DailyMed label
  4. Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol 2008. PMC2439524
  5. Chung T, et al. Effects of testosterone and nandrolone on cardiac function: a randomized, placebo-controlled study. Clin Endocrinol (Oxf) 2007. PMID 17223994
  6. Crawford BA, et al. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 2003. PMID 12843161
  7. Camara LC, et al. Nandrolone Decanoate for Postmenopausal Osteoporosis: A Systematic Review and Meta-Analysis of Randomized Trials. Cureus 2025. PMC12748007
  8. Bijlsma JW, et al. Influence of nandrolondecanoate on the pituitary-gonadal axis in males. Acta Endocrinol (Copenh) 1982. PMID 6812344
  9. Belkien L, et al. Pharmacokinetics of 19-nortestosterone esters in normal men. J Steroid Biochem 1985. PMID 4010287
  10. Wijnand HP, et al. Pharmacokinetic parameters of nandrolone (19-nortestosterone) after intramuscular administration of nandrolone decanoate (Deca-Durabolin) to healthy volunteers. Acta Endocrinol Suppl 1985. PMID 3865478
  11. Minto CF, et al. Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: effects of ester, injection site and injection volume. J Pharmacol Exp Ther 1997. PMID 9103484
  12. Singh GK, et al. Pharmacokinetic-pharmacodynamic study of subcutaneous injection of depot nandrolone decanoate using dried blood spots sampling coupled with ultrapressure liquid chromatography tandem mass spectrometry assays. J Clin Endocrinol Metab 2014. PMID 24684468
  13. Johansen KL, et al. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA 1999. PMID 10208142
  14. Gold J, et al. Effects of nandrolone decanoate compared with placebo or testosterone on HIV-associated wasting. HIV Med 2006. PMID 16494628
  15. Frisoli A Jr, et al. The effect of nandrolone decanoate on bone mineral density, muscle mass, and hemoglobin levels in elderly women with osteoporosis: a double-blind, randomized, placebo-controlled clinical trial. J Gerontol A Biol Sci Med Sci 2005. PMID 15972619
  16. Health Canada. Drug Product Database, product information: DECA DURABOLIN INJ 50MG/ML (DIN 00022462), Organon Canada. Health Canada DPD
  17. Johansen KL, et al. Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: a randomized, controlled trial. J Am Soc Nephrol 2006. PMID 16825332
  18. Storer TW, et al. A randomized, placebo-controlled trial of nandrolone decanoate in human immunodeficiency virus-infected men with mild to moderate weight loss with recombinant human growth hormone as active reference treatment. J Clin Endocrinol Metab 2005. PMID 15914526
  19. Mulligan K, et al. Effect of nandrolone decanoate therapy on weight and lean body mass in HIV-infected women with weight loss: a randomized, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2005. PMID 15767536
  20. Creutzberg EC, et al. A role for anabolic steroids in the rehabilitation of patients with COPD? A double-blind, placebo-controlled, randomized trial. Chest 2003. PMID 14605042
  21. Hartgens F, et al. Body composition and anthropometry in bodybuilders: regional changes due to nandrolone decanoate administration. Int J Sports Med 2001. PMID 11354529
  22. van Marken Lichtenbelt WD, et al. Bodybuilders' body composition: effect of nandrolone decanoate. Med Sci Sports Exerc 2004. PMID 15076791
  23. Geusens P. Nandrolone decanoate: pharmacological properties and therapeutic use in osteoporosis. Clin Rheumatol 1995. PMID 8846659
  24. Hartgens F, et al. Prospective echocardiographic assessment of androgenic-anabolic steroids effects on cardiac structure and function in strength athletes. Int J Sports Med 2003. PMID 12868045
  25. Hartgens F, et al. Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). Br J Sports Med 2004. PMID 15155420
  26. US Drug Enforcement Administration. 21 CFR 1308.13 Schedule III. Electronic Code of Federal Regulations, 2026. 21 CFR 1308.13
  27. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA 2026 list
  28. Palonek E, et al. Atypical excretion profile and GC/C/IRMS findings may last for nine months after a single dose of nandrolone decanoate. Steroids 2016. PMID 26853157
  29. Magnolini R, et al. Evaluation of implementing drug checking services for anabolic androgenic steroids in Switzerland: a pilot study. Harm Reduct J 2025. PMC12147309